Member Info for Morgank

See todays RNS, Re Ovarian Cancer Pre-study results

SUCCESSFUL COMPLETION OF OVARIAN CANCER PRE-STUDY

‘Pre-study demonstrates ANGLE's optimised sample-to-answer molecular solution with patient samples

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is delighted to announce that the first phase of its ovarian cancer clinical verification study ("the pre-study") has reported positive results.’

I would expect positive news flow over the coming months from what todays RNS indicated, SP as expected, sell on the news. I personally think this is one to stay invested in and it will reward the patient longer term investor.

Current target price 130p

http://investing.thisismoney.co.uk/broker-views/

Angle PLC Positive Results from FDA Clinical Study

Source: UK Regulatory (RNS & others)
TIDMAGL

RNS Number : 6723A

Angle PLC

31 May 2019


For immediate release 31 May 2019

ANGLE plc ("the Company")

POSITIVE RESULTS FROM FDA CLINICAL STUDY

Analytical studies ongoing to support FDA submission

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is delighted to announce positive results from its Parsortix FDA clinical study for metastatic breast cancer.

The 400 subject ANG-002 clinical study (the Study) was designed to support a De Novo submission to the United States Food and Drug Administration (FDA) seeking Class II regulatory clearance for ANGLE's Parsortix(TM) system for the intended use with metastatic breast cancer patients.

The Study has achieved its primary objective to demonstrate the ability of the Parsortix system to capture and harvest cancer cells from the blood of a significant proportion of metastatic breast cancer patients.

The Study has also achieved its exploratory goals by demonstrating that the cells harvested from patient blood using the Parsortix system could be interrogated using different subsequent analysis techniques, including: Wright-Giemsa staining of cytospin preparations for cytopathological evaluation, fluorescent in situ hybridisation (FISH) for evaluation of HER2/neu amplification status, and RT-qPCR for evaluation of cancer related gene expression levels. The harvested cells were also able to be used for the generation of cDNA libraries of sufficient quality for use in RNA-seq evaluation, full bioinformatic analysis is due in June.

ANGLE's ongoing discussions with FDA as part of the De Novo process have recently identified additional analytical study experiments that will be needed to support FDA clearance. It is helpful that these requirements have been identified ahead of FDA submission. The additional studies have minimal cost and are expected to be completed to allow FDA submission in early Q4 CY19 offering the prospect of FDA clearance in early CY20. The timing of FDA regulatory clearance is dependent on the FDA's review and response to our submission.

Further disclosure of data will be reserved to optimise the potential for publication in peer-reviewed journals and to present the data at leading cancer conferences.

ANGLE Founder and Chief Executive, Andrew Newland, commented:

"We are delighted with the positive results from the FDA clinical study. We are working to complete the remaining analytical study work and the full data analysis and interpretation so that an FDA submission can be made as soon as possible.

"We believe there is a tremendous opportunity for ANGLE to secure the first ever FDA clearance(1) for a platform that captures and harvests intact circulating tumour cells from patient blood for subsequent analysis, in the first instance for metastatic breast cancer. This clearance, considered the gold standard for approva

Fiat Chrysler and Renault are in advanced talks to merge the automakers
PUBLISHED 4 MINS AGO

Phil LeBeau
@Lebeaucarnews

Fiat Chrysler and France's Renault are in talks to form a partnership

https://twitter.com/ConnectSourceWA/status/1131347732382265344?s=20

Two odd trades posted @ 0.5476 both 200k, must be an error, i hope

Yes just recently 1 and 2 million buys and sells are common place and the sp does not change.
I guess with over 3 billion shares issued a million or two is negligible and you can buy a million for around 30k.
Let’s hope for news soon , GLA

Yes tiny rise in SP but in the right direction. Nice latte trade

Yes i agree , Lombard increasing there holding from 4.99 % (reported 21/2/18) to 10.69%.

SEE on website has them @ 2.77% , but TR1 today indicates they have come from 8.77%, have i missed a notification ??

Like your theory Terrym, SP just simmering waiting for lift off we hope !

Still some large trades being made, difficult to work out buys and sell at the moment, i would expect some holding RNS’s soon due to the new large issuance.

The SP has already responded to the dilution by falling from 5.5 to 3.0 in line with the 50% new issuance.

The additional contract win has done precious little , we need forecast of breakeven a lot sooner to move the needle by winning more contracts. Trouble is they have upfront costs, with revenue further down the line.
I think a large increase in Fleet would help short term

Well the dilution cursed the SP to drop from 5.5 to 3 which was inline with the extra 50% issuance so we already had it

Seeing Machines Limited Result of GM, Offer and Total Voting Rights

Source: UK Regulatory (RNS & others)
TIDMSEE

RNS Number : 7720W

Seeing Machines Limited

23 April 2019

23 April 2019

Seeing Machines Limited

Result of General Meeting, Offer and Total Voting Rights

Result of General Meeting

Seeing Machines Limited (AIM: SEE, "Seeing Machines" or the "Group"), the advanced computer vision technology company that designs AI-powered operator monitoring systems to improve transport safety, is pleased to report that, further to the announcements on 20 and 22 March 2019 relating to the conditional Placing and Subscriptions to raise gross proceeds of GBP27.77 million (approximately AUD51.3 million), all resolutions put to shareholders at the General Meeting held earlier today were duly passed.

Result of Offer

In addition, Seeing Machines is pleased to announce that valid acceptance have been received in respect of, and the Company will issue, 126,794,082 new Ordinary Shares (the "Offer Shares") at a price of 3 pence per Offer Share pursuant to the Offer, resulting in gross proceeds received under the Offer of GBP3.8 million (approximately AUD6.9 million).

Accordingly, pursuant to the Placing, Subscriptions and Offer, the Company has raised gross proceeds of GBP31.57 million. The Placing, Subscriptions and Offer remain conditional on admission of the Placing Shares and Subscription Shares becoming effective at 8.00 a.m. on 24 April 2019 ("Admission").

Total Voting Rights

Application has been made for a total of 1,052,402,416 Ordinary Shares to be admitted to trading on 24 April 2019. With effect from Admission, the total issued share capital of the Group will be 3,365,214,334 Ordinary Shares with no Ordinary Shares held in treasury. Therefore, the total number of voting rights in the Group will be 3,365,214,334 and this figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interest in, or a change to their interest in Seeing Machines.

Ken Kroeger, CEO of Seeing Machines, said:

"We are very pleased with the continued support of our shareholders. The automotive and fleet sectors are increasingly recognising the risks posed by driver inattention and fatigue in single vehicles as well as across commercial and passenger transport.

"Our industry leading driver monitoring technology, developed over many years, has been consistently validated through regulatory and government recommendations globally and with seven automotive OEM programs.

"These additional funds will be instrumental in ensuring that we are well placed to continue to leverage the market opportunities as they rapidly grow and evolve."

Enquiries:


+61 2 6103
Seeing Machines Limited www.seeingmachines.com 4700
Ken Kroeger - CEO
Sophie Nicoll - VP, Marketing & C

That’s some news flow with more to follow, FinnCap maintain sp target 110p which i think we can make and when FDA approval comes in surely interest from others .
GLA, hold in there

VIEW FULL AGL PROFILE VIEW PROFILE
ANGLE PLC TIMELINE

ARTICLE
Thu
ANGLE SHARES RISE 11% AFTER ITS TUMOUR CELL DETECTION DEVICE IS DEPLOYED IN CANCER ADVANCE
NEWSWIRE
April 12 2019
ANGLE GROUND-BREAKING LIQUID BIOPSY TO BE USED IN LUNG CANCER STUDY
NEWSWIRE
April 04 2019
ANGLE’S PARSORTIX LIQUID BIOPSY GETTING LOTS OF EXPOSURE AT WORLD’S BIGGEST CANCER CONFERENCE
ARTICLE
March 07 2019
ANGLE PASSES KEY MILESTONE RECRUITMENT IS COMPLETED FOR PHASE III CLINICAL TRIAL OF ITS LIQUID BIOPS
NEWSWIRE
February 28 2019
“SIGNIFICANT MILESTONE” FOR ANGLE AS IT KICKS OFF SECOND OVARIAN CANCER STUDY
NEWSWIRE
February 25 2019
ANGLE: RESEARCHERS FIND NEW USE FOR COMPANY'S CANCER CELL HARVESTING DEVICE
ARTICLE
February 11 2019
ANGLE TECHNOLOGY USED IN CUTTING-EDGE RESEARCH FEATURED IN SCIENCE JOURNAL NATURE
BIG PICTURE
February 01 2019
ANGLE’S PARSORTIX LIQUID BIOPSY PROVING TO BE MORE THAN JUST A CANCER DETECTION DEVICE
NEWSWIRE
January 31 2019
ANGLE ON TRACK TO COMPLETE KEY PARSORTIX STUDY IN CURRENT QUARTER
ARTICLE
January 29 2019
ANGLE DEVICE HAS LYMPH NODE POTENTIAL, SAYS GERMAN RESEARCH TEAM
VIEW ALL STORIES

Broker views for Angle PLC
This table is a guide to the latest buy, sell, hold and target price forecasts from the big City banks and brokers.
MARKET DATA

Date
Broker
Recomm.
Current price
Price when issued
Old target price
New target price
Notes
18 Apr 2019 finnCap Corporate 74.50 68.50 110.00 - Unchanged

Angle PLC Parsortix used in new cancer assessment technique

Source: RNS Non-Regulatory
TIDMAGL

Angle PLC

18 April 2019


For immediate release 18 April 2019

ANGLE plc ("the Company")

MD ANDERSON DEVELOPS NEW TECHNIQUE FOR ASSESSING CANCER USING PARSORTIX

Study published in leading peer-reviewed publication Nature

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce that top US cancer centre, the University of Texas MD Anderson Cancer Center has developed a new technique for assessing the metastatic potential of breast cancer using ANGLE's Parsortix(TM) system.

The technique Transmembrane Receptor Dynamics (TReD) measures the dynamics of cytoskeletal structure and mechanical properties of live cancer cells held within the microfluidic Parsortix cassette using an optical interrogation technique. The development work has been published in the peer-reviewed publication, Nature.

The publication states that the TReD approach can serve "as a new biophysical marker to probe the metastatic potential of cancer cells and even to monitor the transition of metastasis". This offers the potential to differentiate highly invasive cancer cells from non to less-invasive cancer cells allowing more personalised treatment to be offered to the patient.

The technique is a significant advance on current approaches because "it can deal with suspended cells and does not require mechanical contact or applied force with cells under examination". Current approaches have a variety of key limitations including being technically challenging and/or labour intensive, requiring physical interaction with the cell and cannot be undertaken on live cells. The researchers state that TReD can be easily performed within the Parsortix system.

The work published in the journal Nature is available at

https://angleplc.com/library/publications/.

ANGLE Founder and Chief Executive, Andrew Newland, commented:

"This study is the 19(th) peer-reviewed publication by a leading independent cancer centre demonstrating successful use of ANGLE's world leading Parsortix CTC system. We are pleased to see new applications of the system being developed by independent users of Parsortix, all of which add to the body of evidence and generate new commercial opportunities."

For further information ANGLE:


ANGLE plc +44 (0) 1483 343434
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
finnCap Ltd (NOMAD and Joint Broker)
Corporate Finance - Carl Holmes, Simon
Hicks, Max Bullen-Smith
ECM - Alice Lane +44 (0)20 7220 0500
WG Partners (Joint Broker)
Nigel Barnes, Nigel Birks, Andrew Craig,
Chris Lee +44 (0) 203 705 9330
FTI Consulting
Simon Conway, Ciara Martin +44 (0) 203 727 1000
Matthew Ventimiglia (US) +1